Boothbay Fund Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Boothbay Fund Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-19,700	Closed	-$346K	–	2457
2021 Q3	$346K	Sell	19,700 -1,600	-8%	-$18.7K	0.01%	1260
2021 Q2	$207K	Buy	21,300 +21,087	+9,900%	+$198K	0.01%	1509
2021 Q1	$229K	Hold	213	–	–	0.01%	1311
2020 Q4	$313K	Buy	+213	New	+$3.07K	0.01%	933

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Boothbay Fund Management's TRIL Position: Q4 2021 in Review

Boothbay Fund Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 20,977 shares — an estimated $368K sold.

Boothbay Fund Management first reported a position in TRIL in Q3 2018 and held it in 7 quarters. The position peaked at $368K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Boothbay Fund Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Boothbay Fund Management sold 20,977 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $368K.
Boothbay Fund Management first reported a position in Trillium Therapeutics Inc. in Q3 2018 and held it in 7 quarters.
Boothbay Fund Management's Trillium Therapeutics Inc. position peaked at $368K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.